159 related articles for article (PubMed ID: 23209818)
1. Prenatal treatment prevents learning deficit in Down syndrome model.
Incerti M; Horowitz K; Roberson R; Abebe D; Toso L; Caballero M; Spong CY
PLoS One; 2012; 7(11):e50724. PubMed ID: 23209818
[TBL] [Abstract][Full Text] [Related]
2. Prevention of developmental delays in a Down syndrome mouse model.
Toso L; Cameroni I; Roberson R; Abebe D; Bissell S; Spong CY
Obstet Gynecol; 2008 Dec; 112(6):1242-1251. PubMed ID: 19037032
[TBL] [Abstract][Full Text] [Related]
3. Prevention of learning deficit in a Down syndrome model.
Incerti M; Toso L; Vink J; Roberson R; Nold C; Abebe D; Spong CY
Obstet Gynecol; 2011 Feb; 117(2 Pt 1):354-361. PubMed ID: 21252750
[TBL] [Abstract][Full Text] [Related]
4. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.
Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737
[TBL] [Abstract][Full Text] [Related]
5. Reversal of alcohol-induced learning deficits in the young adult in a model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Wood L; Abebe D; Spong CY
Obstet Gynecol; 2010 Feb; 115(2 Pt 1):350-356. PubMed ID: 20093910
[TBL] [Abstract][Full Text] [Related]
6. Prenatal peptide treatment appears promising in Down syndrome mouse model.
Levenson D
Am J Med Genet A; 2013 Mar; 161A(3):ix. PubMed ID: 23436390
[No Abstract] [Full Text] [Related]
7. Treatment with neuropeptides attenuates c-fos expression in a mouse model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Abebe D; Spong CY
Am J Perinatol; 2010 Oct; 27(9):743-8. PubMed ID: 20446212
[TBL] [Abstract][Full Text] [Related]
8. Learning enhancement with neuropeptides.
Toso L; Endres M; Vink J; Abebe DT; Brenneman DE; Spong CY
Am J Obstet Gynecol; 2006 Apr; 194(4):1153-8; discussion 1158-9. PubMed ID: 16580319
[TBL] [Abstract][Full Text] [Related]
9. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I; Sragovich S; Schirer Y; Idan-Feldman A
J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
[TBL] [Abstract][Full Text] [Related]
10. Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.
Zhou FC; Fang Y; Goodlett C
Alcohol Clin Exp Res; 2008 Aug; 32(8):1361-71. PubMed ID: 18565153
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective peptides influence cytokine and chemokine alterations in a model of fetal alcohol syndrome.
Roberson R; Kuddo T; Benassou I; Abebe D; Spong CY
Am J Obstet Gynecol; 2012 Dec; 207(6):499.e1-5. PubMed ID: 23174390
[TBL] [Abstract][Full Text] [Related]
12. Prevention of the alcohol-induced changes in brain-derived neurotrophic factor expression using neuroprotective peptides in a model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Benassou I; Abebe D; Spong CY
Am J Obstet Gynecol; 2010 May; 202(5):457.e1-4. PubMed ID: 20452488
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanism of learning enhancement: NMDA and GABA receptor expression.
Toso L; Johnson A; Bissell S; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2007 Sep; 197(3):267.e1-4. PubMed ID: 17826414
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective peptides prevent some alcohol-induced alteration in gamma-aminobutyric acid A-beta3, which plays a role in cleft lip and palate and learning in fetal alcohol syndrome.
Toso L; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2007 Mar; 196(3):259.e1-5. PubMed ID: 17346546
[TBL] [Abstract][Full Text] [Related]
15. Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome.
Blanchard J; Bolognin S; Chohan MO; Rabe A; Iqbal K; Grundke-Iqbal I
J Neuropathol Exp Neurol; 2011 Dec; 70(12):1070-9. PubMed ID: 22082658
[TBL] [Abstract][Full Text] [Related]
16. Protective peptides that are orally active and mechanistically nonchiral.
Brenneman DE; Spong CY; Hauser JM; Abebe D; Pinhasov A; Golian T; Gozes I
J Pharmacol Exp Ther; 2004 Jun; 309(3):1190-7. PubMed ID: 15007105
[TBL] [Abstract][Full Text] [Related]
17. Novel peptides prevent alcohol-induced spatial learning deficits and proinflammatory cytokine release in a mouse model of fetal alcohol syndrome.
Vink J; Auth J; Abebe DT; Brenneman DE; Spong CY
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 1):825-9. PubMed ID: 16150281
[TBL] [Abstract][Full Text] [Related]
18. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective fractalkine in fetal alcohol syndrome.
Roberson R; Kuddo T; Benassou I; Abebe D; Spong C
Am J Obstet Gynecol; 2011 May; 204(5):400.e1-3. PubMed ID: 21572545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
